Science1 distinct publisher3 min readUpdated
A matched comparison of 471 burn patients found shorter stays and half the complication rate with intact cod skin. The trial now running does not test that comparison.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
The complication gap is the number to hold, not the bed-days. Sixteen per cent against 8 per cent [8] means roughly 12 or 13 patients have to receive intact fish skin instead of a synthetic substitute for one case of sepsis or similar to be avoided [4]. That is a large effect for a temporary wound covering, and large effects in matched retrospective data are the ones most likely to shrink once somebody randomises.
The arms were nowhere near equal. Ninety-nine patients got GraftGuide and about 372 got approved synthetic substitutes [4][1], so the fish skin group is roughly a fifth of the cohort [2]. Matching covered age, sex, burn severity and size, and other complications from the injury [5], which is sensible as far as it goes; the data still spans 49 centres and a window from 2019 to 2025 [3], and a discharge date is partly a property of the institution writing it. Kerecis, which makes the product, funded the work and according to the published account did not analyse the data [9]. Fiona Wood at the University of Western Australia puts the milder version of the objection: comparing equivalent patients on different treatments is always difficult, and formal head-to-head trials are what settle it [14].
The proposed mechanism is thinner than the outcome. John Lantis at the Icahn School of Medicine at Mount Sinai notes that fish skin resembles human skin under a microscope, so "maybe it works like [our] skin" [10], and points to unpublished data in which omega-3 on a burn produces an initial spike of inflammation that stops bleeding and then fades [11]. Neither proposition is tested by this dataset.
What is concrete is the processing. Because very few fish viruses are thought to affect people, the skin does not need the harsh detergents that would wash the omega-3 out [12], and a cod is large enough to yield a useful amount of skin per animal [13]. That is a manufacturing argument rather than a clinical one, and it is the reason a fishery byproduct can sit on the same shelf as a synthesised collagen scaffold [2].
The trial being run to firm this up asks a different question. Each participant gets fish skin on part of the burn and a graft on the rest, so every patient is their own control [15], which removes the matching problem entirely. But it is testing whether fish skin reduces the need for grafts in second-degree burns [15], while the retrospective was in patients whose burns were mostly third-degree or mixed-depth and who went on to be grafted anyway [6]. The head-to-head Wood asks for, cod skin against a collagen scaffold in deep burns, is not the one under way.
Scale is why this matters more than a single sponsored analysis should. More than 30,000 people a day develop burns needing medical attention [16], which is upwards of 10.9 million a year [5]. Only a slice of those reach a burn centre, but against that denominator a 12-day difference in length of stay [7] is a bed capacity question, and bed capacity is a bad thing to settle on the manufacturer's own data.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Kerecis, an Icelandic company, manufactures products made from wild Atlantic cod (Gadus morhua) that are approved to treat burns and other wounds in the US and the UK.
Before graft surgery, many burn patients undergo temporary wound coverage, which can involve synthetic or biosynthetic scaffolds made up of collagen.
Lantis and colleagues used data from 471 adults who attended 49 burn centres between 2019 and 2025.
Prior to a skin graft, 99 of the patients were treated with GraftGuide, a minimally processed intact fish skin from Kerecis; the remaining patients received approved synthetic substitutes.
The two groups were matched for factors like age, sex, burn severity and size, and any other complications from the injury.
The adults had burns affecting 13 per cent of their body on average, and most burns were either mixed, affecting multiple layers of skin, or third-degree.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Sponsor-funded retrospective matched comparison, no published statistics
The outcome differences are large and drawn from a multi-centre cohort, but the design is a matched retrospective comparison with only 99 treated patients, the funder is the product's manufacturer, no confidence intervals, p-values or publication venue are supplied, the mechanistic support is explicitly unpublished, and the one independent expert quoted says formal head-to-head trials are still needed.
Cleared in two major markets, modest documented clinical use
There is concrete adoption evidence: regulatory approval for burns and wounds in the US and UK, and documented use as pre-graft coverage in 99 patients across a network of 49 burn centres over six years, plus an active prospective trial. But no market share, unit volume, formal guideline placement or purchasing data is supplied, and the fish-skin arm was only about a fifth of the studied cohort.
Framing outruns the study design
The coverage opens with fish skin as possibly 'the safest and most effective way of treating severe burns' and headlines faster healing, while the underlying material is a manufacturer-funded retrospective matched cohort with a 99-patient exposure arm, an unpublished mechanism, and an expert caveat that head-to-head trials are needed; the ongoing trial tests a different endpoint entirely, a mismatch the coverage does not flag.
Manufacturer funded the study and its author supplies the mechanism narrative
Kerecis, which sells GraftGuide, funded the analysis that favours its product, and the investigator quoted throughout on mechanism, safety and sourcing advantages is the study's lead author who is also involved in the company's ongoing trial. The only counterweight in the material is a single independent expert calling for head-to-head trials.
Single publisher, single study, disclosures clear but detail thin
Every fact here traces to one article reporting one sponsor-funded analysis; there is no second outlet, no primary publication, no statistical detail and no regulatory document in the supplied set. Confidence is moderate that the reported figures were stated as described and low that they will survive prospective testing.
science
Mount Sinai puts a youth protein on aging microglia, and the mice answer1 distinct publisher
science
Patent-likeness scoring leaves the lab, and your abstract becomes the interface1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 21, 2026